Author / Glenn Murphy
-
Therapeutic Innovations Stand Out to Investors at Triangle Venture Day
Mon, 09/29/2025 Kyle Marshall, NCBiotech Original article: https://www.ncbiotech.org/news/therapeutic-innovations-stand-out-investors-triangle-venture-day If you want to know how therapeutic innovation in the Triangle stacks up against other life sciences hubs, just ask an investor who knows the national and global landscape. Nima Ronaghi, principal at Breakout Ventures, a San Francisco fund that invests in early-stage, science-backed companies, said the…
-
C-Path Launches Global Collaborative to Advance Drug Development for Neonatal Brain Injury
TUCSON, Ariz., June 20, 2025 — The Critical Path Institute® (C-Path), through its International Neonatal Consortium (INC), is proud to announce the official launch of the Neonatal Brain Injury Collaborative (NBIC) — a global, pre-competitive initiative aimed at accelerating the development of safe and effective therapies for conditions such as hypoxic-ischemic encephalopathy (HIE) and neonatal white matter injury.
-
Tellus Therapeutics Secures Seed Financing to Develop the First Treatment for Newborns with WMI
DURHAM, N.C, May 12, 2021 –(BUSINESS WIRE)– Tellus Therapeutics, Inc., a biopharmaceutical company developing TT-20 as a treatment for white matter injury (WMI) and myelin repair in premature babies, today announced a seed investment from Xontogeny, LLC to advance their lead program through IND-enabling work.